| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/26/2008 | CN100376573C 1,3-dihydroimidazole fused-ring compound |
| 03/26/2008 | CN100376570C Dioxolane analogs for improved inter-cellular delivery |
| 03/26/2008 | CN100376569C Inhibitors of farnesyl protein transferase |
| 03/26/2008 | CN100376567C Qinazoline derivatives as VEGF inhibitors |
| 03/26/2008 | CN100376564C Substituted heterocyclic benzoeycloalkenes and the use thereof as substances having analgesic effect |
| 03/26/2008 | CN100376554C N-substituted indol-3-glyoxylamid with antiasthmatic, antiallergic and immunosuppressive/immunomodulating effect |
| 03/26/2008 | CN100376530C Vitamin D analogues |
| 03/26/2008 | CN100376281C A compound preparation for resisting chicken heat stress |
| 03/26/2008 | CN100376279C Medicine and food dual purpose Chinese medicine for preventing and treating summer heat damp diarrhea and its manufacturing method |
| 03/26/2008 | CN100376255C Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatary activity and anti-atherogenic activity |
| 03/26/2008 | CN100376242C 2-aryl-propionic acid and medicine composition containing same |
| 03/25/2008 | US7348440 Mitotic kinesin inhibitors |
| 03/25/2008 | US7348433 3-[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-quinolin-2(1H)-ones or 5--[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-pyrrolo[3,2,1-IJ]quinolin-4(4H)-ones; type E antagonists; analgesics, antipyretics, antiinflammatory agents; side effect reduction |
| 03/25/2008 | US7348431 Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor |
| 03/25/2008 | US7348426 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 03/25/2008 | US7348400 α-conotoxin peptides with analgesic properties |
| 03/25/2008 | US7348359 Retinoid X receptor modulators |
| 03/25/2008 | US7348355 Treating obesity with the Microsomal triglyceride transfer protein inhibitor (S) N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and another lipid lowering agent such as a statin or fibrate |
| 03/25/2008 | US7348353 Acetylene derivatives having mGluR 5 antagonistic activity |
| 03/25/2008 | US7348351 for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis |
| 03/25/2008 | US7348341 Chemical compounds |
| 03/25/2008 | US7348339 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent |
| 03/25/2008 | US7348336 Inhibitors of IkB kinase (I Kappa B Kinase); 1-acetyl-7-bromo- beta -carboline; antiinflammatory and anticarcinogenic agent; asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, infections, and cardiac infarct |
| 03/25/2008 | US7348333 Treating bone disorder caused by osteoclasts, tumor growth and tumor metastasis, prophylaxis of cardiovascular disorders, nephropathies or retinopathies |
| 03/25/2008 | US7348327 (2S)-4,4-difluoro-1-(2-{[1-(2-pyrazinyl)piperidin-4-yl]amino}acetyl)-2-pyrrolidine carbonitrile; enzyme inhibitors; diabetes |
| 03/25/2008 | US7348326 in brain; (2,5-difluorodifluorophenyl)-N-methyl-N-((1-propylbenzimidazol-2-yl)methyl)carboxamide; anxiolitic and antidepressant; finding and altering the signal-transducing activity of gamma aminobutyric acid (GABA) receptors; detectably-labeled antagonist/agonist of GABAR |
| 03/25/2008 | US7348324 Cyclic amine compounds as CCR5 antagonists |
| 03/25/2008 | US7348318 α-Amino-N-(diaminophosphinyl)lactam derivatives |
| 03/25/2008 | US7348313 Administering carrier molecule such as albumin conjugated to mannose-6-phosphate; particularly targeting Hepatic Stellate Cells (HSC); glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, Crohn's disease, colitis ulcerosa, glomerulonephritis and sepsis; diagnosis |
| 03/25/2008 | US7348306 Peptide with a sequence selected from the group consisting of Ser-Leu-Ile-Gly-Arg-Leu-NH2, and trans-cynnamoyl-Leu-Ile-Gly-Arg-Leu-ornithine-NH2 combined with amastatins for activation of protease activated receptor-2; eye drop solution for contact lenses |
| 03/25/2008 | US7348173 Fatty-acid amide hydrolase |
| 03/25/2008 | US7348155 Method for identifying compounds for treating aging processes in the coronary circulatory system |
| 03/25/2008 | US7348138 Diagnostic methods and kits for identifying individuals exposed to West Nile virus or other viruses including Flavivirus or Pestivirus |
| 03/25/2008 | US7348032 Using plant extracts as antiproliferative agents |
| 03/25/2008 | US7348017 such as 2-[Benzyl[(4-methoxyphenyl)sulfonyl]amino]-N-(3-thioxo-3H-1,2,4-dithiazol-5-yl)acetoamide; cosmetics; antiaging agents |
| 03/25/2008 | US7348000 Therapeutic compositions and methods of treating glycolipid storage related disorders |
| 03/25/2008 | CA2426754C Indolocarbazole anticancer agents and methods of using them |
| 03/25/2008 | CA2419077C A method of treating a systemic disease |
| 03/25/2008 | CA2359987C 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 03/25/2008 | CA2299308C Cyclohexenone long-chain alcohol and medicament containing same |
| 03/25/2008 | CA2277273C Integrin antagonists |
| 03/25/2008 | CA2268709C Hiv protease inhibitors |
| 03/25/2008 | CA2264822C Cocoa components, edible products having enhanced polyphenol content, methods of making same and medical uses |
| 03/25/2008 | CA2243578C High affinity nucleic acid ligands of complement system proteins |
| 03/25/2008 | CA2228281C Use of l-carnitine and acyl l-carnitines for lowering ceramide levels |
| 03/25/2008 | CA2174707C Chromone derivatives as nk1 and substance p antagonists |
| 03/25/2008 | CA2173319C Radiation sensitization using texaphyrins |
| 03/25/2008 | CA2164642C Novel compounds having a benzisoselen-azoline and -azine structure, method for preparing same and therapeutic uses thereof |
| 03/25/2008 | CA2073500C Compositions and methods for detecting and modulating rna activity and gene expression |
| 03/20/2008 | WO2008034117A2 Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal |
| 03/20/2008 | WO2008033858A2 Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| 03/20/2008 | WO2008033375A2 Long lasting drug formulations |
| 03/20/2008 | WO2008033239A2 Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof |
| 03/20/2008 | WO2008032876A1 Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same |
| 03/20/2008 | WO2008032814A1 Aspirin-containing pharmaceutical agent |
| 03/20/2008 | WO2008032764A1 Fused heterocyclic derivative |
| 03/20/2008 | WO2008032696A1 Preventive or therapeutic agent for respiratory disease |
| 03/20/2008 | WO2008032665A1 Novel phenylacetic acid derivative |
| 03/20/2008 | WO2008031233A1 Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases |
| 03/20/2008 | WO2008003667A3 Combinations of monoamine reuptake inhibitors and potassium channel activators |
| 03/20/2008 | WO2007124447A3 Use of chalcogenides for treating shock and other adverse conditions |
| 03/20/2008 | US20080071069 For delivering DNA/RNA into cells |
| 03/20/2008 | US20080071068 Cytoplasmic Localization Dna and Rna |
| 03/20/2008 | US20080071066 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 03/20/2008 | US20080071065 Fibroblast Growth Factor-Like Polypeptides |
| 03/20/2008 | US20080070996 Transfers a D-glucuronic acid residue to an N-acetyl-D-galactosamine residue when the N-acetyl-D-galactosamine residue is present at the non-reducing end of the chondroitin backbone, or transfers an N-acetyl-D-galactosamine residue to a D-glucuronic acid residue |
| 03/20/2008 | US20080070983 2-O- (Beta-D-Glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 03/20/2008 | US20080070980 or esters; promoting an increased protein formation and/or prevention of loss of proteins in humans and animals due to an adverse health condition; increased protein formation in sports and workout activities; during aging |
| 03/20/2008 | US20080070978 cloprostenol or latanoprost; topical use; highly crystalline structures that are easy to formulate into ophthalmic solutions; hydrolysis of these analogs does not have toxic and irritant small aliphatic alcohol coproducts; hypotensive agent for intraocular pressure |
| 03/20/2008 | US20080070975 methylnaltrexone, a calcium salt, chelating agent in aqueous solution; calcium salts of EDTA, DTPA, HEDTA, EGTA, nitrilotriacetic acid or calcium citrate; reducing severity of side effects from use of analgesic opioids; effective delivery without degradation under refrigeration and/or room temperature |
| 03/20/2008 | US20080070970 Novel indole derivatives as selective androgen receptor modulators (sarms) |
| 03/20/2008 | US20080070964 Opioid receptor active compounds |
| 03/20/2008 | US20080070962 Cannabinoid receptor antagonist; N-{[5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]methyl}-3-cyanobenzenesulfonamide; psychiatric disorder, substance dependence and withdrawal disorder, cognitive disorder, ADD, neurodegenerative diseases, pain, eating disorders, dyslipidemia, ulcer |
| 03/20/2008 | US20080070959 Guanylhydrazone compounds, compositions, methods of making and using |
| 03/20/2008 | US20080070948 Including indanones, indolinones and benzoxazolinones containing a piperidine ring, e.g., 1-[3-(4-(Hydroxymethyl)piperidin-1-yl)propyl]-1,3-dihydrobenzoimidazol-2-one; particularly for the M1 and/or M4 receptor subtypes; increase acetylcholine signaling or effect in the brain |
| 03/20/2008 | US20080070938 HMG-CoA reductase inhibitor and pyridoxine, pyridoxal, or pyridoxamine; combination therapy; pravastatin, simvastatin, atorvastatin |
| 03/20/2008 | US20080070932 unexpectedly potent antagonists of A2a adenosine receptor; Parkinson's; neurodegenerative diseases; 2-furan-2-yl-N5-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine |
| 03/20/2008 | US20080070931 5-phenyl-nicotinamide derivatives |
| 03/20/2008 | US20080070928 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative |
| 03/20/2008 | US20080070914 Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent |
| 03/20/2008 | US20080070913 Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors |
| 03/20/2008 | US20080070908 Compositions including antibiotics and methods for using same |
| 03/20/2008 | US20080070907 Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods |
| 03/20/2008 | US20080070906 Quinolinone derivatives |
| 03/20/2008 | US20080070903 New pyrimidine derivatives and new pyridine derivatives |
| 03/20/2008 | US20080070902 Cinnamide Compound |
| 03/20/2008 | US20080070900 Administering galantamine or galantamine hydrobromide antidotes to a human at a risk of exposure to parathion or malathion toxicity, subsequently administering atropine as an antimuscarinic agen. |
| 03/20/2008 | US20080070897 Having high bioavailability levels and reduced variability of bioavailability by use of dispersed, colloidal structures, colloids or analogous structures of the drug, a hydrophilic component (ethanol) , a surfactant such as polyglycerol, polyoxyethylene castor oil |
| 03/20/2008 | US20080070887 Diaryl Ether Derivatives and Uses Thereof |
| 03/20/2008 | US20080070886 Anti-cancer combinations |
| 03/20/2008 | US20080070884 Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability |
| 03/20/2008 | US20080070869 Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators |
| 03/20/2008 | US20080070866 Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example |
| 03/20/2008 | US20080070856 Medicament to treat a fibrotic disease |
| 03/20/2008 | US20080070850 Have a linker molecule that misaligns the carbohydrate cores; structurally simpler, easier to synthesize, and more potent; low toxicity; anticancer; 1,1'-O-2,2',3,3',4,4',6,6'-tetrakis(3,4,5-trihydroxybenzoyl)- beta , beta '-D,D'-glucopyranosylterephthalate |
| 03/20/2008 | US20080070843 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics |
| 03/20/2008 | US20080070831 Endothelial growth factor; isolated polypeptide; stimulates cell proliferation, neovascularization, vascular system permeability; uses thereof in medical and diagnostic applications |
| 03/20/2008 | US20080070827 Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg coa reductase, and increase ldl receptor and sp1 expression in a mammal |
| 03/20/2008 | US20080070229 Method for preserving organs for transplantation |
| 03/20/2008 | US20080069897 Method for promoting and maintaining respiratory tract health |